vs
Pacira BioSciences, Inc.（PCRX）与PREFORMED LINE PRODUCTS CO（PLPC）财务数据对比。点击上方公司名可切换其他公司
Pacira BioSciences, Inc.的季度营收约是PREFORMED LINE PRODUCTS CO的1.0倍（$177.4M vs $173.1M），PREFORMED LINE PRODUCTS CO净利率更高（4.9% vs 1.6%，领先3.2%），Pacira BioSciences, Inc.同比增速更快（5.0% vs 3.6%），过去两年PREFORMED LINE PRODUCTS CO的营收复合增速更高（10.8% vs -0.2%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
预成型线路产品公司（PLPC）研发、生产和销售适用于输配电、通信及可再生能源基建领域的工程硬件组件，服务全球多地的公用事业、网络运营商及工业客户，提供可提升网络可靠性与运营效率的解决方案。
PCRX vs PLPC — 直观对比
营收规模更大
PCRX
是对方的1.0倍
$173.1M
营收增速更快
PCRX
高出1.4%
3.6%
净利率更高
PLPC
高出3.2%
1.6%
两年增速更快
PLPC
近两年复合增速
-0.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $173.1M |
| 净利润 | $2.9M | $8.4M |
| 毛利率 | — | 29.8% |
| 营业利润率 | 3.9% | 6.8% |
| 净利率 | 1.6% | 4.9% |
| 营收同比 | 5.0% | 3.6% |
| 净利润同比 | — | -19.3% |
| 每股收益（稀释后） | $0.07 | $1.72 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXPLPC
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $173.1M | ||
| Q3 25 | $179.5M | $178.1M | ||
| Q2 25 | $181.1M | $169.6M | ||
| Q1 25 | $168.9M | $148.5M | ||
| Q4 24 | $187.3M | $167.1M | ||
| Q3 24 | $168.6M | $147.0M | ||
| Q2 24 | $178.0M | $138.7M |
净利润PCRXPLPC
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $8.4M | ||
| Q3 25 | $5.4M | $2.6M | ||
| Q2 25 | $-4.8M | $12.7M | ||
| Q1 25 | $4.8M | $11.5M | ||
| Q4 24 | — | $10.5M | ||
| Q3 24 | $-143.5M | $7.7M | ||
| Q2 24 | $18.9M | $9.4M |
毛利率PCRXPLPC
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 29.8% | ||
| Q3 25 | 80.9% | 29.7% | ||
| Q2 25 | 77.4% | 32.7% | ||
| Q1 25 | 79.7% | 32.8% | ||
| Q4 24 | 78.7% | 33.3% | ||
| Q3 24 | 76.9% | 31.1% | ||
| Q2 24 | 75.1% | 31.9% |
营业利润率PCRXPLPC
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 6.8% | ||
| Q3 25 | 3.5% | 7.4% | ||
| Q2 25 | 4.7% | 10.1% | ||
| Q1 25 | 1.2% | 8.8% | ||
| Q4 24 | 13.2% | 10.5% | ||
| Q3 24 | -82.8% | 7.1% | ||
| Q2 24 | 15.9% | 8.1% |
净利率PCRXPLPC
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 4.9% | ||
| Q3 25 | 3.0% | 1.5% | ||
| Q2 25 | -2.7% | 7.5% | ||
| Q1 25 | 2.8% | 7.8% | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | -85.1% | 5.2% | ||
| Q2 24 | 10.6% | 6.8% |
每股收益（稀释后）PCRXPLPC
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $1.72 | ||
| Q3 25 | $0.12 | $0.53 | ||
| Q2 25 | $-0.11 | $2.56 | ||
| Q1 25 | $0.10 | $2.33 | ||
| Q4 24 | $0.38 | $2.13 | ||
| Q3 24 | $-3.11 | $1.54 | ||
| Q2 24 | $0.39 | $1.89 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | — |
| 总债务越低越好 | — | $38.3M |
| 股东权益账面价值 | $653.9M | $475.5M |
| 总资产 | $1.2B | $653.6M |
| 负债/权益比越低杠杆越低 | — | 0.08× |
8季度趋势，按日历期对齐
现金及短期投资PCRXPLPC
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | — | ||
| Q3 25 | $246.3M | — | ||
| Q2 25 | $445.9M | — | ||
| Q1 25 | $493.6M | — | ||
| Q4 24 | $484.6M | — | ||
| Q3 24 | $453.8M | — | ||
| Q2 24 | $404.2M | — |
总债务PCRXPLPC
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $38.3M | ||
| Q3 25 | $376.7M | $36.0M | ||
| Q2 25 | $580.5M | $31.8M | ||
| Q1 25 | $583.4M | $29.1M | ||
| Q4 24 | $585.3M | $20.8M | ||
| Q3 24 | — | $27.2M | ||
| Q2 24 | — | $31.6M |
股东权益PCRXPLPC
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $475.5M | ||
| Q3 25 | $727.2M | $466.3M | ||
| Q2 25 | $757.8M | $460.7M | ||
| Q1 25 | $798.5M | $435.8M | ||
| Q4 24 | $778.3M | $422.3M | ||
| Q3 24 | $749.6M | $429.0M | ||
| Q2 24 | $879.3M | $416.2M |
总资产PCRXPLPC
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $653.6M | ||
| Q3 25 | $1.3B | $644.6M | ||
| Q2 25 | $1.5B | $631.5M | ||
| Q1 25 | $1.6B | $592.5M | ||
| Q4 24 | $1.6B | $573.9M | ||
| Q3 24 | $1.5B | $592.0M | ||
| Q2 24 | $1.6B | $572.6M |
负债/权益比PCRXPLPC
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 0.08× | ||
| Q3 25 | 0.52× | 0.08× | ||
| Q2 25 | 0.77× | 0.07× | ||
| Q1 25 | 0.73× | 0.07× | ||
| Q4 24 | 0.75× | 0.05× | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | 0.08× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $21.9M |
| 自由现金流经营现金流 - 资本支出 | — | $11.8M |
| 自由现金流率自由现金流/营收 | — | 6.8% |
| 资本支出强度资本支出/营收 | — | 5.9% |
| 现金转化率经营现金流/净利润 | — | 2.60× |
| 过去12个月自由现金流最近4个季度 | — | $33.3M |
8季度趋势，按日历期对齐
经营现金流PCRXPLPC
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $21.9M | ||
| Q3 25 | $60.8M | $18.9M | ||
| Q2 25 | $12.0M | $26.9M | ||
| Q1 25 | $35.5M | $5.7M | ||
| Q4 24 | $33.1M | $24.1M | ||
| Q3 24 | $53.9M | $9.4M | ||
| Q2 24 | $53.2M | $28.3M |
自由现金流PCRXPLPC
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $11.8M | ||
| Q3 25 | $57.0M | $8.3M | ||
| Q2 25 | $9.3M | $18.6M | ||
| Q1 25 | $26.9M | $-5.3M | ||
| Q4 24 | $31.0M | $20.6M | ||
| Q3 24 | $49.8M | $5.8M | ||
| Q2 24 | $51.6M | $24.6M |
自由现金流率PCRXPLPC
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 6.8% | ||
| Q3 25 | 31.7% | 4.7% | ||
| Q2 25 | 5.1% | 10.9% | ||
| Q1 25 | 15.9% | -3.6% | ||
| Q4 24 | 16.6% | 12.3% | ||
| Q3 24 | 29.6% | 3.9% | ||
| Q2 24 | 29.0% | 17.7% |
资本支出强度PCRXPLPC
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 5.9% | ||
| Q3 25 | 2.2% | 6.0% | ||
| Q2 25 | 1.5% | 4.9% | ||
| Q1 25 | 5.1% | 7.4% | ||
| Q4 24 | 1.1% | 2.1% | ||
| Q3 24 | 2.4% | 2.4% | ||
| Q2 24 | 0.9% | 2.7% |
现金转化率PCRXPLPC
| Q1 26 | — | — | ||
| Q4 25 | — | 2.60× | ||
| Q3 25 | 11.20× | 7.21× | ||
| Q2 25 | — | 2.12× | ||
| Q1 25 | 7.37× | 0.49× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | 2.82× | 3.02× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
PLPC
暂无分部数据
